Giuseppe Ciliberti, Stefano Cangemi, Francesca Musella, Federico Fortuni, Francesco Piroli, Enrica Vitale, Stefano Cornara, Daniela Zabbia, Antonella Spinelli, Serena Guasti, Stefania Marazia, Piero Gentile, Federico Nardi, Fabrizio Oliva, Massimo Grimaldi, Marco Metra, Massimo Imazio, Benedetta De Chiara
{"title":"[Ten questions about cardiac sarcoidosis].","authors":"Giuseppe Ciliberti, Stefano Cangemi, Francesca Musella, Federico Fortuni, Francesco Piroli, Enrica Vitale, Stefano Cornara, Daniela Zabbia, Antonella Spinelli, Serena Guasti, Stefania Marazia, Piero Gentile, Federico Nardi, Fabrizio Oliva, Massimo Grimaldi, Marco Metra, Massimo Imazio, Benedetta De Chiara","doi":"10.1714/4663.46751","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiac sarcoidosis is a rare but potentially life-threatening condition characterized by the formation of non-caseating granulomas in the myocardium. Clinical manifestations range from asymptomatic forms to atrioventricular blocks, ventricular arrhythmias, heart failure, and sudden cardiac death. Diagnostic work-up requires a multimodality approach combining advanced imaging, clinical criteria, and, when possible, histological confirmation. Immunosuppressive therapy remains the cornerstone of treatment, aimed at suppressing myocardial inflammation and preventing irreversible damage. Risk stratification for sudden cardiac death is crucial, and cardiac implantable electronic devices play a key role in selected patients. This review, structured in ten clinical questions, provides an overview of the epidemiology, clinical presentation, diagnostic criteria, differential diagnosis, therapeutic strategies, and risk stratification of cardiac sarcoidosis, in light of the most recent international guidelines and consensus documents.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"27 4","pages":"237-248"},"PeriodicalIF":1.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4663.46751","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Cardiac sarcoidosis is a rare but potentially life-threatening condition characterized by the formation of non-caseating granulomas in the myocardium. Clinical manifestations range from asymptomatic forms to atrioventricular blocks, ventricular arrhythmias, heart failure, and sudden cardiac death. Diagnostic work-up requires a multimodality approach combining advanced imaging, clinical criteria, and, when possible, histological confirmation. Immunosuppressive therapy remains the cornerstone of treatment, aimed at suppressing myocardial inflammation and preventing irreversible damage. Risk stratification for sudden cardiac death is crucial, and cardiac implantable electronic devices play a key role in selected patients. This review, structured in ten clinical questions, provides an overview of the epidemiology, clinical presentation, diagnostic criteria, differential diagnosis, therapeutic strategies, and risk stratification of cardiac sarcoidosis, in light of the most recent international guidelines and consensus documents.